MY ACCOUNT | NEWSLETTER |

Kinetics of Regenerating Protein 3E and C-Reactive Protein in Healthy Dogs, Dogs Undergoing Tibial Plateau Leveling Osteotomy, and Dogs With Sepsis.

Clinical evidence update from Veterinary clinical pathology


Clinical Context

Peer-reviewed veterinary literature continues to shape everyday decision-making for canine patients, especially when new evidence clarifies diagnosis, treatment selection, monitoring, or clinical outcomes.

What the Study Evaluated

A study published in Veterinary clinical pathology in 2026 evaluated kinetics of Regenerating Protein 3E and C-Reactive Protein in Healthy Dogs, Dogs Undergoing Tibial Plateau Leveling Osteotomy, and Dogs With Sepsis..

Key Findings

Serial measurements of acute-phase proteins help monitor the development of and recovery from sepsis in people and dogs. To date, the kinetics of regenerating protein (REG) 3E, a novel biomarker for inflammation in dogs, are unknown. The goal of our study was to assess changes in the concentrations of REG3E and compare these to C-reactive protein (CRP) concentrations over 48-72 h in different cohorts of dogs. Plasma REG3E concentrations were measured using an ELISA on 3-4 consecutive days from 43 dogs, including 12 healthy controls, 17 undergoing tibial plateau leveling osteotomy (TPLO), and 14 with sepsis. Canine CRP was measured using a...

Why It Matters for Veterinary Professionals

For veterinary professionals, the practical value of this work lies in how the findings may support more structured clinical assessment, clearer monitoring, and more informed decisions for canine patients.

Practical Interpretation

The results should be interpreted in the context of the study design, population, inclusion criteria, and clinical setting. Application in practice should consider patient-specific risk factors, available diagnostics, local standards of care, and clinician judgment.

Clinical Takeaway

Overall, the study adds useful evidence for clinicians seeking to align daily practice with current veterinary research while maintaining a balanced, case-by-case approach.

Read the full article here.

Like0
Dislike0
  • Please enter a comment


Name *
Email address *
Comment *


* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @ grupoasis.com, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.


I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies



More news

MagnaWave redefines the standard for PEMF technology with M Line

Like0
Dislike0

Reversible congestive heart failure associated with diabetes mellitus in two cats.

Like0
Dislike0

Use of Intraperitoneal Lidocaine in Horses Undergoing Laparotomy for Colic.

Like0
Dislike0

Manufacturing & Supply

Like0
Dislike0

On the road and in the barn: The delicate balance of equine ambulatory care

Like0
Dislike0

Newsletter

 
 

News of interest

EVENTS

Copyright © 2026 - All Rights Reserved
ISSN 2768-198X

Top